Lack Of Funding Has “Hobbled” FDA Postmarketing Drug Safety Work – IoM
This article was originally published in The Tan Sheet
Executive Summary
Congress must approve "substantially increased" funding resources to improve FDA's drug safety system and implement much needed widespread change, according to a final report from the Institute of Medicine
You may also be interested in...
Fixed Term For FDA Commissioner Could Bring Mixed Results For Industry
Drug and device law attorneys say a fixed term for the FDA commissioner could stabilize oversight and attract leaders who are more like professional managers than political operatives, but might not insulate the agency from political influence.
Fixed Term For FDA Commissioner Could Bring Mixed Results For Industry
Drug and device law attorneys say a fixed term for the FDA commissioner could stabilize oversight and attract leaders who are more like professional managers than political operatives, but might not insulate the agency from political influence.
FDA Misses User Fee Goals As Resources Tighten For Reviews, SPAs
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program